Literature DB >> 1534101

Mechanisms of experimental cancer cachexia. Interaction between mononuclear phagocytes and colon-26 carcinoma and its relevance to IL-6-mediated cancer cachexia.

G Strassmann1, C O Jacob, R Evans, D Beall, M Fong.   

Abstract

In a recent report we showed that IL-6 is an important mediator of experimental cancer cachexia in the colon-26 (C-26) tumor system. In culture, on a per cell basis, C-26.IVX cell line (which develops tumors and induces severe cachexia of syngeneic hosts) produces up to 60-fold less IL-6 than single cell suspensions prepared from freshly excised tumors. In this study, the mechanism behind this observation was investigated. Analysis of the cellular composition of progressing C-26 tumors indicated they contained up to 6% of macrophages. T cells, B cells, and granulocytes were not detected in the tumors. Because C-26.IVX line grown in vitro contained no macrophages, the possibility that macrophage products may augment IL-6 synthesis by the tumor cells was tested. Indeed, IL-1 beta in a dose-dependent manner and at picogram amounts could potentiate IL-6 production by the C-26 cell line. The presence of high affinity receptors for IL-1 on the C-26.IVX cell line was established. These cells expressed approximately 1500 IL-1 sites per cell with a dissociation constant of approximately 20 pM. Next, we attempted to mimic the situation in vivo by coculture of C-26.IVX cells with syngeneic peritoneal macrophages and found that this condition gives rise to an augmented IL-6 production similar to that observed with in vivo derived tumor cells or rIL-1 beta-treated C-26.IVX cells. Furthermore, anti-IL-1 type I receptor antibody completely blocked C-26.IVX IL-6 production induced by either rIL-1 beta or by peritoneal macrophages. Taken together, these data suggest a pathway of IL-6 production by C-26 tumors that involves a cellular interaction between IL-1R-expressing tumor cells and host-derived macrophages. The results also suggest that this interaction significantly contributes to cachectic events endured by the tumor-bearing host.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1534101

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  25 in total

Review 1.  Anorexia in cancer: role of feeding-regulatory peptides.

Authors:  Simona Perboni; Akio Inui
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2006-07-29       Impact factor: 6.237

2.  Conjugation of cisplatin analogues and cyclooxygenase inhibitors to overcome cisplatin resistance.

Authors:  Wilma Neumann; Brenda C Crews; Menyhárt B Sárosi; Cristina M Daniel; Kebreab Ghebreselasie; Matthias S Scholz; Lawrence J Marnett; Evamarie Hey-Hawkins
Journal:  ChemMedChem       Date:  2014-10-15       Impact factor: 3.466

3.  Macrophage-derived tumor necrosis factor and tumor-derived of leukemia inhibitory factor and interleukin-6: possible cellular mechanisms of cancer cachexia.

Authors:  K G Billingsley; D L Fraker; G Strassmann; C Loeser; H M Fliot; H R Alexander
Journal:  Ann Surg Oncol       Date:  1996-01       Impact factor: 5.344

4.  Myeloid-derived suppressor cell inhibition of the IFN response in tumor-bearing mice.

Authors:  Bethany L Mundy-Bosse; Gregory B Lesinski; Alena C Jaime-Ramirez; Kristen Benninger; Mahmood Khan; Periannan Kuppusamy; Kristan Guenterberg; Sri Vidya Kondadasula; Abhik Ray Chaudhury; Krista M La Perle; Melanie Kreiner; Gregory Young; Denis C Guttridge; William E Carson
Journal:  Cancer Res       Date:  2011-06-16       Impact factor: 12.701

5.  Interleukin-6 involvement in mesothelioma pathobiology: inhibition by interferon alpha immunotherapy.

Authors:  H Bielefeldt-Ohmann; A L Marzo; R P Himbeck; A G Jarnicki; B W Robinson; D R Fitzpatrick
Journal:  Cancer Immunol Immunother       Date:  1995-04       Impact factor: 6.968

Review 6.  Are cytokines possible mediators of cancer cachexia?

Authors:  Y Noguchi; T Yoshikawa; A Matsumoto; G Svaninger; J Gelin
Journal:  Surg Today       Date:  1996       Impact factor: 2.549

7.  Suramin interferes with interleukin-6 receptor binding in vitro and inhibits colon-26-mediated experimental cancer cachexia in vivo.

Authors:  G Strassmann; M Fong; C E Freter; S Windsor; F D'Alessandro; R P Nordan
Journal:  J Clin Invest       Date:  1993-11       Impact factor: 14.808

8.  The presence of tumor necrosis factor-alpha and its antibody in the sera of cachexic patients with gastrointestinal cancer.

Authors:  T Kiyama; M Onda; A Tokunaga; I Fujita; T Okuda; T Mizutani; N Matsukura; Y Todome; H Ohkuni
Journal:  Surg Today       Date:  1994       Impact factor: 2.549

9.  Splenectomy before tumor inoculation prolongs the survival time of cachectic mice.

Authors:  K Soda; M Kawakami; S Takagi; A Kashii; M Miyata
Journal:  Cancer Immunol Immunother       Date:  1995-10       Impact factor: 6.968

10.  Patho- and immunobiology of malignant mesothelioma: characterisation of tumour infiltrating leucocytes and cytokine production in a murine model.

Authors:  H Bielefeldt-Ohmann; D R Fitzpatrick; A L Marzo; A G Jarnicki; R P Himbeck; M R Davis; L S Manning; B W Robinson
Journal:  Cancer Immunol Immunother       Date:  1994-12       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.